Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No approved treatments are currently available for acquired hypothalamic obesity. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for acquired hypothalamic obesity, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for acquired hypothalamic obesity. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
2 clinical trials registered, 1 recruiting. Interventions under study include drug therapy. Pipeline includes 2 PHASE3. Research is primarily industry-sponsored.
18 publications have been identified in PubMed for acquired hypothalamic obesity. Research spans Review / Meta-Analysis (56%), Epidemiology / Natural History (22%), and Clinical Trial Publication (11%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 10 | 56% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 10:46 PM UTC
European rare disease database
Common questions about acquired hypothalamic obesity
Designated
Exclusivity End |
|---|
Designation Status |
|---|
Tesofensine plus metoprolol in a fixed-dose combination | Tesofensine plus metoprolol in a fixed-dose combination | Saniona S/A | 2021 | — | Designated |
2 trials found
Disease patterns and progression |
4 |
22% |
Clinical study results | 2 | 11% |
Other research | 1 | 6% |
Patient case studies | 1 | 6% |
Witte J (2026). [PMID: 41236025](https://pubmed.ncbi.nlm.nih.gov/41236025/). *J Neuroendocrinol*. [Epidemiology / Natural History]
Müller HL (2026). [PMID: 41224353](https://pubmed.ncbi.nlm.nih.gov/41224353/). *Endocr J*. [Review / Meta-Analysis]
Lambert F (2026). [PMID: 41153084](https://pubmed.ncbi.nlm.nih.gov/41153084/). *Diabetes Obes Metab*. [Epidemiology / Natural History]
Mete Kalayci F (2026). [PMID: 42209772](https://pubmed.ncbi.nlm.nih.gov/42209772/). *Endocrine*. [Epidemiology / Natural History]
van Santen HM (2026). [PMID: 39819748](https://pubmed.ncbi.nlm.nih.gov/39819748/). *Horm Res Paediatr*. [Review / Meta-Analysis]
van Santen HM (2026). [PMID: 41943709](https://pubmed.ncbi.nlm.nih.gov/41943709/). *Diabetes Obes Metab*. [Review / Meta-Analysis]
Roth CL (2026). [PMID: 41678022](https://pubmed.ncbi.nlm.nih.gov/41678022/). *Drugs*. [Review / Meta-Analysis]
Müller HL (2026). [PMID: 42064767](https://pubmed.ncbi.nlm.nih.gov/42064767/). *Front Endocrinol (Lausanne)*. [Review / Meta-Analysis]
Lang H (2026). [PMID: 41624164](https://pubmed.ncbi.nlm.nih.gov/41624164/). *Obes Pillars*. [Case Report / Case Series]
van Santen HM (2025). [PMID: 40746184](https://pubmed.ncbi.nlm.nih.gov/40746184/). *Endocr Rev*. [Review / Meta-Analysis]
AI-curated news mentioning acquired hypothalamic obesity
Updated May 12, 2026
Recent research explores melanocortin-4 receptor agonist treatment for hypothalamic obesity in ROHHAD syndrome. This study highlights potential therapeutic avenues for managing obesity in affected patients.
Rhythm Pharmaceuticals receives FDA approval for Imcivree, a treatment for hypothalamic obesity, potentially generating over $2 billion in global sales. This approval follows a challenging Phase 3 trial, marking a significant recovery for the company.